These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 32499195)

  • 41. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G
    Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
    [No Abstract]   [Full Text] [Related]  

  • 42. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 43. Orphan Drugs in Oncology.
    Korchagina D; Jaroslawski S; Jadot G; Toumi M
    Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Health Impact Fund: a potential solution to inequity in global drug access.
    Banerjee A; Pogge T
    Indian J Med Ethics; 2010; 7(4):240-3. PubMed ID: 22106579
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ethical considerations in orphan drug approval and use.
    Kesselheim AS
    Clin Pharmacol Ther; 2012 Aug; 92(2):153-5. PubMed ID: 22814660
    [TBL] [Abstract][Full Text] [Related]  

  • 46. MSJAMA: Orphan diseases and adoptive initiatives.
    Iribarne A
    JAMA; 2003 Jul; 290(1):116. PubMed ID: 12837724
    [No Abstract]   [Full Text] [Related]  

  • 47. The need for worldwide policy and action plans for rare diseases.
    Forman J; Taruscio D; Llera VA; Barrera LA; Coté TR; Edfjäll C; Gavhed D; Haffner ME; Nishimura Y; Posada M; Tambuyzer E; Groft SC; Henter JI;
    Acta Paediatr; 2012 Aug; 101(8):805-7. PubMed ID: 22519914
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Alignment of health technology assessments and price negotiations for new drugs for rare disorders in Canada: Does it lead to improved patient access?
    Rawson NSB
    J Popul Ther Clin Pharmacol; 2020 Feb; 27(1):e48-e64. PubMed ID: 32124580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The orphan drug backlash.
    Maeder T
    Sci Am; 2003 May; 288(5):80-7. PubMed ID: 12701333
    [No Abstract]   [Full Text] [Related]  

  • 50. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary].
    Szegedi M; Molnár MJ; Boncz I; Kosztolányi G
    Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rare disease resources not as rare as one might think.
    Burnworth MT
    Am J Health Syst Pharm; 2013 Jun; 70(12):1013-4. PubMed ID: 23719873
    [No Abstract]   [Full Text] [Related]  

  • 52. [European incentives for orphan medicinal products].
    Enzmann H; Lütz J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA program could boost treatments for neglected diseases.
    Traynor K
    Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098
    [No Abstract]   [Full Text] [Related]  

  • 54. Crowdfunding not fit for clinical trials.
    Cheah PY
    Nature; 2015 Nov; 527(7579):446. PubMed ID: 26607536
    [No Abstract]   [Full Text] [Related]  

  • 55. A checklist for clinical trials in rare disease: obstacles and anticipatory actions-lessons learned from the FOR-DMD trial.
    Crow RA; Hart KA; McDermott MP; Tawil R; Martens WB; Herr BE; McColl E; Wilkinson J; Kirschner J; King WM; Eagle M; Brown MW; Hirtz D; Lochmuller H; Straub V; Ciafaloni E; Shieh PB; Spinty S; Childs AM; Manzur AY; Morandi L; Butterfield RJ; Horrocks I; Roper H; Flanigan KM; Kuntz NL; Mah JK; Morrison L; Darras BT; von der Hagen M; Schara U; Wilichowski E; Mongini T; McDonald CM; Vita G; Barohn RJ; Finkel RS; Wicklund M; McMillan HJ; Hughes I; Pegoraro E; Bryan Burnette W; Howard JF; Thangarajh M; Campbell C; Griggs RC; Bushby K; Guglieri M
    Trials; 2018 May; 19(1):291. PubMed ID: 29793540
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Drugs for rare diseases: the blessing of being orphans.].
    Costa E; Schieppati A; Luzzatto L; Remuzzi G
    Recenti Prog Med; 2019 May; 110(5):221-229. PubMed ID: 31140454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drugs for rare disorders.
    Cremers S; Aronson JK
    Br J Clin Pharmacol; 2017 Aug; 83(8):1607-1613. PubMed ID: 28653488
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Regulatory considerations for developing drugs for rare diseases: orphan designations and early phase clinical trials.
    Pariser AR; Xu K; Milto J; Coté TR
    Discov Med; 2011 Apr; 11(59):367-75. PubMed ID: 21524390
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Law and research could add up to profitable niche drugs.
    Haefner B
    Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
    [No Abstract]   [Full Text] [Related]  

  • 60. A discrete choice experiment investigating preferences for funding drugs used to treat orphan diseases: an exploratory study.
    Mentzakis E; Stefanowska P; Hurley J
    Health Econ Policy Law; 2011 Jul; 6(3):405-33. PubMed ID: 21205401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.